Uses of Meirara

Meirara is a mandatory prescription drug indicated in the treatment of advanced breast cancer in postmenopausal women who have failed other medical treatments. So what is the effect of the drug Meirara? What are the precautions when using the drug?

Meirara has the main ingredient Letrozole - a non-steroidal aromatase enzyme inhibitor, inhibits estrogen biosynthesis and is resistant to cancer cells.
Mechanism of action by inhibiting aromatase enzymes by binding to cytosolic pigment enzymes. In postmenopausal women, estrogen is mainly synthesized by the action of the aromatase enzyme, which converts adrenal androgens - mainly androstenedione and testosterone - into estrone (E1) and estradiol (E2). Inhibition of estrogen synthesis in peripheral tissues and in the tumor itself can reduce the size and proliferation of cancer cells.
Meirara is rapidly and completely absorbed from the gastrointestinal tract, about 60% bound to plasma proteins, mainly to albumins. Bioavailability is close to 100%; Finally excreted in feces (4%), urine (88%) as metabolites and as unchanged Letrozole.

Meirara is indicated for the treatment of the following pathologies:
Breast cancer in postmenopausal women, treatment failure with tamoxifen or other anti-estrogens. Patients with early invasive breast cancer in postmenopausal women have received previous treatment with tamoxifen to no avail. Postmenopausal women with hormone receptor-positive breast cancer prior to mastectomy. Do not use Meirara in the following cases:
Allergy to the ingredient letrozole or any other ingredient of the drug. Pre-menopausal women, pregnant or lactating women, pediatric patients, male patients with breast cancer are not indicated to use Meirara. Patients with severe liver failure. If breast cancer is hormone receptor negative, do not use Meirara. Note when using Meirara
Check renal function before and during use in patients with renal failure with glomerular filtration rate less than 10 ml/min. Meirara strongly reduces the amount of estrogen in the blood, causing a sharp decrease in bone mineralization. Therefore, women with osteoporosis or at risk of osteoporosis should use caution when using the drug.

There is no evidence to prove the effectiveness when combining Meirara with other cancer drugs. Drug interactions of Meirara with other therapeutic drugs have not been detected. However, before combining with any drug, it is necessary to consult a specialist.

Meirara is formulated as a film-coated tablet. Take the pill as a whole, do not separate or crush it.
Dosage
Starting dose: 2.5mg x 1 time/day. Drink 1-2 hours after eating; continuously for 5 years to support treatment or use until the tumor recurs. After Tamoxifen therapy, treat with Meirara for 3 years or until tumor recurs, whichever comes first. Dosage in elderly patients does not require adjustment. All doses are for reference only, depending on the condition and condition of the patient, the doctor will give different dosage indications. In case of overdose or missed dose, it is necessary to notify medical staff for treatment.

Some unwanted effects may be encountered when using Meirara
Face flushing, red rash, urticaria. Joint pain, muscle pain. Loss of appetite or appetite, nausea, vomiting, gastrointestinal disturbances, diarrhea, constipation. Blood cholesterol disorders. Headache, dizziness, fatigue, neurasthenia. Increased sweating, weight gain, hair loss. Osteoporosis. Urinary infection . Memory loss, insomnia. Taste disorder. Palpitations, increased heart rate, venous thrombosis, high blood pressure, myocardial infarction. Vaginal dryness, white discharge, breast pain. Pulmonary artery thrombosis, cerebral ischemia. In summary, Meirara is an adjunct to the treatment of advanced breast cancer in postmenopausal women. In addition to the therapeutic effect of the drug, it also causes a lot of bad reactions to the body, so the use of the drug must be strictly monitored and tested by medical staff.